Notice of Meeting, 61635 [2019-24649]

Download as PDF Federal Register / Vol. 84, No. 219 / Wednesday, November 13, 2019 / Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Vascular and Hematology Research Enhancement Award Application Review. Date: December 5, 2019. Time: 1:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Natalia Komissarova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5207, MSC 7846, Bethesda, MD 20892, (301) 435– 1206, komissar@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in Toxicology and Pharmacology. Date: December 5, 2019. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Atul Sahai, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, (301) 435– 1198 sahaia@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: November 6, 2019. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–24614 Filed 11–12–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of Meeting Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via in person and web conference on December 3rd, 2019, from 9:30 a.m. EST to 4:30 p.m. EST, and December 4th, 2019, from 9:00 a.m. EST to 4:00 p.m. EST. The board will meet in open-session in-person on December 3rd, 2019, from 9:30 a.m. EST to 4:30 p.m. EST to discuss the Mandatory Guidelines for VerDate Sep<11>2014 17:23 Nov 12, 2019 Jkt 250001 Federal Workplace Drug Testing Programs (urine and oral fluid specimens) with updates from the Department of Transportation, Nuclear Regulatory Commission, and the Department of Defense. Other discussion topics include the impact of cannabis laws on drug testing and standard variables. There will be additional presentations from the Division of Workplace Programs’ staff on urine, oral fluid, hair Mandatory Guidelines; and the electronic chain of custody. The board will meet in closedsession in-person on December 4th, 2019, from 9:00 a.m. EST to 4:00 p.m. EST to discuss confidential issues surrounding the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair), HHS drug panel review, preliminary and unpublished studies from the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU); recommendations to the Assistant Secretary for Mental Health and Substance Use regarding additional drugs (fentanyl and methadone) that may be tested for in the future, and lastly, program financials. Therefore, the December 4th, 2019, from 9:00 a.m. EST to 4:00 p.m. EST, meeting is closed to the public, as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d). Meeting registration information can be completed at https:// snacregister.samhsa.gov/ MeetingList.aspx. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https://www.samhsa.gov/ about-us/advisory-councils/meetings or by contacting the Designated Federal Officer, Jennifer Fan. Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Drug Testing Advisory Board. Dates/Time/Type: December 3, 2019, from 9:30 a.m. to 4:30 p.m. EST: OPEN. December 4, 2019, from 9:00 a.m. to 4:00 p.m. EST: CLOSED. Place: Substance Abuse and Mental Health Services Administration, 5th Floor Pavilion A, B, 5600 Fishers Lane, Rockville, MD 20857. Contact: Jennifer Fan, Senior Pharmacist, Center for Substance Abuse Prevention, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 20857, PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 61635 Telephone: (240) 276–1759, email: jennifer.fan@samhsa.hhs.gov. Anastasia Marie Donovan, Policy Anayst. [FR Doc. 2019–24649 Filed 11–12–19; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Notice of Subcommittee Meetings for the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC) Substance Abuse and Mental Health Services Administration, Department of Health and Human Services. AGENCY: Notice of subcommittee meetings (virtual). ACTION: The Secretary of Health and Human Services (Secretary) announces subcommittee meetings of the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC). The meetings are open to the public and can be accessed via telephone only. Agenda with call-in information will be posted on the SAMHSA website prior to the meetings at: https://www.samhsa.gov/about-us/ advisory-councils/meetings. The meetings will include information on the following focus areas: Data, Access, Treatment and Recovery, Justice, and Finance. Committee Name: Interdepartmental Serious Mental Illness Coordinating Committee (subcommittee meetings). Date/Time/Type: December 4, 2019/9:00 a.m.–10:30 a.m. (EST)/OPEN/Focus Area 3: Treatment and Recovery December 4, 2019/10:45 a.m.–12:15 p.m. (EST)/OPEN/Focus Area 1: Data December 4, 2019/10:45 a.m.–12:15 p.m. (EST)/OPEN/Focus Area 4: Justice December 4, 2019/1:00 p.m.–2:30 p.m. (EST)/OPEN/Focus Area 2: Access and Engagement December 4, 2019/1:00 p.m.–2:30 p.m. (EST)/OPEN/Focus Area 5: Finance ADDRESSES: The meetings will be held virtually. Substantive meeting information and a roster of Committee members is available at the Committee’s website https://www.samhsa.gov/about-us/ advisory-councils/smi-committee. SUPPLEMENTARY INFORMATION: SUMMARY: E:\FR\FM\13NON1.SGM 13NON1

Agencies

[Federal Register Volume 84, Number 219 (Wednesday, November 13, 2019)]
[Notices]
[Page 61635]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-24649]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via in person and web conference on December 
3rd, 2019, from 9:30 a.m. EST to 4:30 p.m. EST, and December 4th, 2019, 
from 9:00 a.m. EST to 4:00 p.m. EST.
    The board will meet in open-session in-person on December 3rd, 
2019, from 9:30 a.m. EST to 4:30 p.m. EST to discuss the Mandatory 
Guidelines for Federal Workplace Drug Testing Programs (urine and oral 
fluid specimens) with updates from the Department of Transportation, 
Nuclear Regulatory Commission, and the Department of Defense. Other 
discussion topics include the impact of cannabis laws on drug testing 
and standard variables. There will be additional presentations from the 
Division of Workplace Programs' staff on urine, oral fluid, hair 
Mandatory Guidelines; and the electronic chain of custody. The board 
will meet in closed-session in-person on December 4th, 2019, from 9:00 
a.m. EST to 4:00 p.m. EST to discuss confidential issues surrounding 
the proposed Mandatory Guidelines for Federal Workplace Drug Testing 
Programs (hair), HHS drug panel review, preliminary and unpublished 
studies from the Johns Hopkins University Behavioral Pharmacology 
Research Unit (BPRU); recommendations to the Assistant Secretary for 
Mental Health and Substance Use regarding additional drugs (fentanyl 
and methadone) that may be tested for in the future, and lastly, 
program financials. Therefore, the December 4th, 2019, from 9:00 a.m. 
EST to 4:00 p.m. EST, meeting is closed to the public, as determined by 
the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in 
accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, 
Section 10(d).
    Meeting registration information can be completed at https://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call 
information will be sent after completing registration. Meeting 
information and a roster of DTAB members may be obtained by accessing 
the SAMHSA Advisory Committees website, https://www.samhsa.gov/about-us/advisory-councils/meetings or by contacting the Designated Federal 
Officer, Jennifer Fan.
    Committee Name: Substance Abuse and Mental Health Services 
Administration, Center for Substance Abuse Prevention, Drug Testing 
Advisory Board.
    Dates/Time/Type: December 3, 2019, from 9:30 a.m. to 4:30 p.m. EST: 
OPEN. December 4, 2019, from 9:00 a.m. to 4:00 p.m. EST: CLOSED.
    Place: Substance Abuse and Mental Health Services Administration, 
5th Floor Pavilion A, B, 5600 Fishers Lane, Rockville, MD 20857.
    Contact: Jennifer Fan, Senior Pharmacist, Center for Substance 
Abuse Prevention, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 
20857, Telephone: (240) 276-1759, email: [email protected].

Anastasia Marie Donovan,
Policy Anayst.
[FR Doc. 2019-24649 Filed 11-12-19; 8:45 am]
BILLING CODE 4162-20-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.